Outcomes of Precision Medicine for Seven Patients With MODY1 or MODY3

Abstract

The efficacy of precision medicine in reducing glycated hemoglobin (HbA1c) levels and the costs of diabetes-related medication in patients with maturity-onset diabetes of the young (MODY) was investigated. The study included two patients with MODY1 and five patients with MODY3 who received their genetic diagnosis and thereafter continued their outpatient care at our university. The HbA1c levels and monthly costs before and 12 months after implementing precision medicine were analyzed. The results revealed that the average HbA1c levels significantly decreased from 7.37 %±1.10 % to 6.29 %±0.48 % (p＜0.05), and the costs of medication significantly decreased from ￥20,153±6,665/month to ￥8,671±8,817/month (p＜0.05). Initially, six of the seven patients were receiving insulin therapy, with three patients receiving four injections per day and the other three receiving three injections per day. After implementing precision medicine, five patients eventually discontinued insulin therapy, including four who switched to taking oral hypoglycemic agents alone. The implementation of precision medicine for patients with a definite diagnosis of MODY1 or MODY3 improved their glycemic control and contributed to reduced medical costs. Importantly, it also helped attenuate the stigma related to having diabetes mellitus. The high prevalence of hepatocellular adenoma-suspected tumors was also shown in patients with MODY3.